The TigerPaw II system for surgical LAA exclusion is associated with a high prevalence of device malfunction, highlighting the need for design improvements to ensure patient safety.
Answers are grounded in this paper and cite their sources.
Single-center TigerPaw II experience supports surgical LAA closure feasibility; leaves open randomized data on stroke prevention.
Exclusion of the left atrial appendage (LAA) may significantly reduce the incidence of stroke associated with atrial fibrillation (AF), since this is the main thrombus source. LAA closure is becoming a therapeutic target for preventing AF-related stroke, attracting much interest in recent years. Different devices are available to provide LAA exclusion during cardiac surgery. We describe herein our experience with the recently introduced TigerPaw II system for LAA exclusion, and report a high prevalence of device malfunction. Design improvements may address these issues and increase safety for new technological devices designed for surgical LAA closure.
No takes yet. Share an insight, caveat, or question.
Ventosa et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: